Citadel Advisors
STLN

Citadel Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Citadel Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Buy
43,400
+16,600
+62% +$50.9K ﹤0.01% 11785
2025
Q4 		$95.4K Buy
26,800
+12,400
+86% +$46K ﹤0.01% 11682
2025
Q3 		$50.3K Buy
+14,400
New +$49.3K ﹤0.01% 12205

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's STLN Position: Q1 2026 in Review

Citadel Advisors opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 608,267 shares worth $1.87M. The stake represents ﹤0.01% of the portfolio and ranks #6215 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in STLN as recently as Q3 2025.

Citadel Advisors first reported a position in STLN in Q1 2021 and has held it in 11 quarters since. The position peaked at $14.6M in Q3 2021. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Citadel Advisors held 608,267 shares of Starling Oncology Institute, Inc. Common Stock worth $1.87M as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Citadel Advisors position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6215 holding.
  • Citadel Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2021 and has held it in 11 quarters since.
  • Citadel Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $14.6M in Q3 2021.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.